Study guide

1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification

C-OBE Obstetric Emergencies Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems

1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness

2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics

2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing

3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion

3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)

4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features

4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia

5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy

5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management

6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean

6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)

7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States

7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive

8 Chapter 8: Acute Intrapartum Delivery Emergencies

8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols

9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma

9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage

10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections

10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies

11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)

12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies

12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications

13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol

14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity

14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies

1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification

Key Takeaways Explain This Topic AI

Cardiovascular disease is the leading non-obstetric cause of maternal mortality; patients classified under modified WHO (mWHO) Class IV conditions (pulmonary arterial hypertension, severe systemic ventricular dysfunction EF <30%, severe native valve stenosis, vascular Ehlers-Danlos, or aortic dilation >45 mm) face extremely high mortality risks and require immediate multidisciplinary cardio-obstetric critical care.

Under current ACOG and CHAP trial guidelines, chronic hypertension in pregnancy requires pharmacologic treatment initiated at a threshold of >=140/90 mmHg to a target blood pressure of <140/90 mmHg using labetalol, extended-release nifedipine, or methyldopa, while ACE inhibitors, ARBs, direct renin inhibitors, and mineralocorticoid receptor antagonists remain strictly contraindicated.

Pregestational diabetes carries an elevated risk of euglycemic diabetic ketoacidosis (DKA) during pregnancy due to lower renal glucose thresholds, accelerated starvation ketogenesis, and placental anti-insulin hormones; intrapartum capillary glucose must be maintained at 70-110 mg/dL to prevent neonatal hypoglycemia.

Prior classical, T-, or J-shaped uterine incisions and extensive transmural myomectomies entering the uterine cavity carry a 4% to 9% catastrophic uterine rupture risk; trial of labor after cesarean (TOLAC) and all prostaglandin cervical ripening agents are absolutely contraindicated, necessitating planned cesarean delivery at 36 0/7 to 37 0/7 weeks.

Acute cocaine and methamphetamine intoxication triggers massive catecholamine release resulting in severe maternal hypertension, coronary vasospasm, and placental abruption; pure beta-blockers must be avoided due to the hazard of unopposed alpha-1 adrenergic vasoconstriction.

Last updated: August 2026

Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification

Obstetric emergency preparedness begins with rigorous antepartum and peripartum risk stratification. Pre-existing maternal comorbidities significantly reduce physiological reserve, alter normal compensatory responses to acute stress, and dramatically increase the risk of maternal morbidity and mortality during labor, delivery, and the puerperium.

1. Maternal Cardiovascular Disease & Modified WHO Risk Stratification

Cardiovascular conditions represent the leading cause of non-obstetric maternal mortality in the United States, accounting for over 26% of pregnancy-related deaths. Normal pregnancy imposes substantial hemodynamic demands: cardiac output increases by 30% to 50%, blood volume expands by 40% to 50%, systemic vascular resistance (SVR) decreases by 20% to 30%, and heart rate increases by 10 to 20 beats per minute. During labor and immediate postpartum autotransfusion, cardiac output surges up to 60% to 80% above baseline. In patients with structural or functional cardiac lesions, these physiological shifts can precipitate acute decompensation, pulmonary edema, lethal arrhythmias, or cardiogenic shock.

The Modified World Health Organization (mWHO) Pregnancy Risk Classification is the gold-standard tool for stratifying maternal cardiovascular risk:

mWHO Class Maternal Risk Profile Clinical Conditions Included Management & Delivery Planning

mWHO Class I No detectable increased risk of mortality; mild increase in morbidity. • Mild pulmonary stenosis; • Patent ductus arteriosus (PDA); • Successfully repaired simple ASD / VSD; • Mitral valve prolapse with trivial regurgitation Local community hospital care; standard obstetric monitoring.

mWHO Class II / II-III Small increase in mortality; moderate morbidity (Class II). Moderate-to-significant increase in mortality/morbidity (Class II-III). • Unoperated ASD / VSD without pulmonary hypertension; • Repaired Tetralogy of Fallot without residual dysfunction; • Turner syndrome without aortic root dilation; • Mild left ventricular (LV) impairment (EF 40–45%); • Hypertrophic cardiomyopathy (HCM); • Native or tissue valve disease not meeting Class IV criteria; • Marfan syndrome without aortic dilation (<40 mm); • Bicuspid aortic valve with aorta <45 mm Followed by specialized cardio-obstetric team; Level II/III maternal care facility; continuous intrapartum telemetry.

mWHO Class III Significant risk of mortality or severe morbidity. • Mechanical heart valves; • Systemic right ventricle (e.g., L-TGA, D-TGA post-Mustard/Senning); • Fontan single-ventricle circulation; • Cyanotic unrepaired heart disease; • Moderate LV dysfunction (EF 30–39%); • Aortic root dilation 40–45 mm in Marfan syndrome or 45–50 mm in bicuspid aortic valve Care at Level IV (Regional Perinatal Health Center) with cardio-obstetric ICU, maternal-fetal medicine (MFM), and cardiothoracic surgery on standby; elective assisted second stage of labor.

mWHO Class IV Extremely high risk of maternal mortality or severe morbidity. Pregnancy is CONTRAINDICATED. • Pulmonary arterial hypertension (PAH) of any etiology (Eisenmenger syndrome, idiopathic PAH); • Severe systemic ventricular dysfunction (LVEF <30% or NYHA Class III–IV); • Severe symptomatic mitral stenosis or severe symptomatic aortic stenosis; • Aortic root dilation >45 mm in Marfan syndrome or >50 mm in bicuspid aortic valve / Turner syndrome; • Vascular Ehlers-Danlos syndrome (vEDS) ; • Prior peripartum cardiomyopathy (PPCM) with residual left ventricular dysfunction If pregnancy occurs, termination should be discussed. If continued, manage exclusively in a Level IV tertiary cardio-obstetric center; early planned delivery via multidisciplinary protocol; strict hemodynamic monitoring (arterial line, central venous access). +---------------------------------------------------------------------------------------------------+

  • | CRITICAL CARDIOVASCULAR EMERGENCY CONSIDERATIONS |
  • | |
  • | 1. PULMONARY ARTERIAL HYPERTENSION / EISENMENGER SYNDROME: |
  • | • Maternal mortality exceeds 20% to 50%, primarily occurring in the first postpartum week. |
  • | • Pathophysiology: Fixed pulmonary vascular resistance prevents the right ventricle from |
  • | accommodating increased preload; drops in SVR cause massive right-to-left shunting, severe |
  • | hypoxemia, and acute right heart failure. Avoid sudden decreases in SVR or hypovolemia. |
  • | |
  • | 2. MECHANICAL HEART VALVES & ANTICOAGULATION: |
  • | • Hypercoagulability of pregnancy significantly increases valve thrombosis risk (up to 10%). |
  • | • Anticoagulation requires strict therapeutic monitoring: therapeutic LMWH (target peak |
  • | anti-Xa 0.8–1.2 IU/mL for aortic/mitral mechanical valves) or adjusted-dose Warfarin. |
  • | • Neuraxial anesthesia requires a minimum 24-hour interval after therapeutic LMWH cessation. |
  • +---------------------------------------------------------------------------------------------------+
  • 2. Chronic Hypertension (CHTN) & Contemporary Blood Pressure Targets

Chronic Hypertension (CHTN) in pregnancy is defined as blood pressure >=140 mmHg systolic and/or >=90 mmHg diastolic that is present before pregnancy or diagnosed prior to 20 weeks of gestation, or persistent hypertension beyond 12 weeks postpartum.

Clinical Impact of the CHAP Trial

Following the landmark Chronic Hypertension and Pregnancy (CHAP) trial, ACOG updated clinical guidelines to recommend active pharmacologic treatment for mild-to-moderate chronic hypertension during pregnancy:

Initiation Threshold: SBP >=140 mmHg or DBP >=90 mmHg (confirmed on two occasions >=4 hours apart).

Target Blood Pressure: Maintain blood pressure <140/90 mmHg (avoiding diastolic BP <60–70 mmHg to preserve uteroplacental perfusion).

First-Line Antihypertensive Regimens

Medication Mechanism of Action Dosage & Administration Key Clinical Pearls & Precautions

Labetalol Combined non-selective beta and selective alpha-1 adrenergic antagonist 100–400 mg PO BID or TID (Maximum: 2,400 mg/day). First-line agent. Avoid in patients with active moderate-to-severe asthma, decompensated heart failure, or severe sinus bradycardia.

Nifedipine (Extended Release) Dihydropyridine calcium channel blocker (peripheral arteriolar vasodilator) 30–60 mg PO once daily (Maximum: 120 mg/day). Excellent once-daily compliance. Do not crush or bite extended-release tablets. Avoid sublingual immediate-release nifedipine (causes unpredictable precipitous hypotension).

Methyldopa Centrally acting alpha-2 adrenergic agonist 250–500 mg PO BID or TID (Maximum: 3,000 mg/day). Long historical safety record, but limited by sedation, depression, and hepatic enzyme elevations. Less potent than labetalol or nifedipine.

Strictly Contraindicated Antihypertensive Classes

ACE Inhibitors (e.g., Lisinopril, Enalapril) and Angiotensin Receptor Blockers (ARBs; e.g., Losartan, Valsartan): Major fetotoxicity causing fetal renal dysgenesis, oligohydramnios sequence (Potter sequence), pulmonary hypoplasia, calvarial bone hypoplasia, intrauterine growth restriction (IUGR), and neonatal anuric renal failure.

Direct Renin Inhibitors (e.g., Aliskiren) and Mineralocorticoid Receptor Antagonists (e.g., Spironolactone): Anti-androgenic effects, abnormal external genitalia development, and severe fetotoxicity.

Superimposed Preeclampsia & Prophylaxis

Patients with chronic hypertension have a 20% to 50% risk of developing superimposed preeclampsia . Baseline screening must include:

Spot urine protein-to-creatinine ratio (UPCR) or 24-hour urine collection (baseline proteinuria >=0.3 mg/mg or >=300 mg/24h).

Baseline serum creatinine, AST/ALT, complete blood count (platelets).

Baseline 12-lead ECG and echocardiogram for longstanding or poorly controlled CHTN.

Low-Dose Aspirin Prophylaxis: Initiate 81–162 mg/day orally between 12 and 16 weeks of gestation (optimally before 16 weeks) and continue daily until delivery to reduce preeclampsia and preterm birth risk.

3. Pregestational Diabetes: Glycemic Targets, DKA & Emergent Complications

Pregestational diabetes mellitus (Type 1 and Type 2) confers heightened risks of maternal diabetic ketoacidosis, preeclampsia (3- to 4-fold increase), operative delivery, postpartum hemorrhage, fetal macrosomia, and shoulder dystocia.

  • Glycemic Control Targets
  • Fasting / Preprandial: 70–95 mg/dL (3.9–5.3 mmol/L)
  • One-hour postprandial: <=140 mg/dL (7.8 mmol/L)
  • Two-hour postprandial: <=120 mg/dL (6.7 mmol/L)

Intrapartum target (active labor / delivery): 70–110 mg/dL (or 80–120 mg/dL per institutional protocol). Maintaining tight intrapartum glycemic control prevents fetal hyperinsulinemia and subsequent catastrophic neonatal hypoglycemia within 1 to 2 hours of birth.

Diabetic Ketoacidosis (DKA) in Pregnancy: The Euglycemic Trap

Pregnancy is an accelerated ketogenic state. Placental secretion of human placental lactogen (hPL), cortisol, progesterone, and placental growth hormone promotes peripheral insulin resistance and rapid lipolysis. The renal threshold for glucose resorption is decreased due to elevated glomerular filtration rate (GFR), leading to glucosuria at lower serum glucose levels. +---------------------------------------------------------------------------------------------------+

  • | OBSTETRIC DKA EMERGENCY ALERT |
  • | |
  • | • DKA in pregnancy can occur at LOWER serum glucose levels than in non-pregnant adults, |
  • | frequently presenting as EUGLYCEMIC DKA (serum glucose <200 mg/dL or even 100–150 mg/dL). |
  • | • Triggers: Beta-mimetic tocolytics (Terbutaline), antenatal corticosteroids (Betamethasone), |
  • | infection/sepsis, insulin non-adherence, hyperemesis gravidarum, or SGLT-2 inhibitor exposure. |
  • | • Fetal Impact: Severe maternal metabolic acidosis (arterial pH <7.20, elevated anion gap, |
  • | high beta-hydroxybutyrate) directly impairs placental gas exchange and fetal oxygenation, |
  • | producing severe Category II/III fetal heart rate tracings (loss of variability, recurrent |
  • | late decelerations). |
  • | • Key Rule: Correct maternal acidosis and volume depletion with IV fluids and insulin FIRST. |
  • | Do NOT perform emergency cesarean delivery for fetal decelerations during acute DKA unless |
  • | maternal resuscitation fails; the fetal tracing almost universally recovers as maternal |
  • | acidemia and perfusion resolve! |
  • +---------------------------------------------------------------------------------------------------+
  • 4. Extreme Obesity (BMI >= 40 kg/m² / Class III Obesity)

Maternal class III obesity (BMI >=40 kg/m²) significantly amplifies emergency operative risks and anesthetic complications across all peripartum stages:

Difficult Airway & Rapid Desaturation: Increased soft tissue deposition in the pharynx, decreased functional residual capacity (FRC), and elevated baseline oxygen consumption cause precipitous maternal desaturation (within 60–90 seconds of apnea). Airway equipment must include video laryngoscopy (e.g., GlideScope), ramped positioning pillows, and short-handled laryngoscope blades.

Neuraxial Challenges & Early Placement: Anatomic landmarks are obscured. Early labor placement of continuous lumbar epidural catheters is strongly recommended to avoid emergency general anesthesia, which carries the highest anesthesia-related maternal mortality.

Vascular Access: Difficult peripheral venous cannulation mandates early placement of dedicated large-bore IVs (16- or 18-gauge) or ultrasound-guided vascular access on admission.

Operative Challenges: Increased risk of emergency cesarean delivery, massive surgical site infection, wound dehiscence, and excessive blood loss. Pannus retraction devices (e.g., Traxi) and silver-impregnated or negative-pressure wound therapy dressings are indicated.

Weight-Adjusted Venous Thromboembolism (VTE) Prophylaxis: Standard fixed-dose heparin/LMWH is insufficient. Enoxaparin dosing should be weight-adjusted (e.g., 0.5 mg/kg SQ every 12 hours or 40 mg SQ BID for BMI 40–50; 60 mg SQ BID for BMI >50) coupled with sequential compression devices (SCDs).

5. Prior Uterine Surgery: Scar Topology & Rupture Risk Stratification

The risk of catastrophic intrapartum uterine rupture is directly determined by the anatomical location, depth, and orientation of previous uterine incisions:

Type of Prior Uterine Surgery Anatomical Characteristics Estimated Uterine Rupture Risk Trial of Labor (TOLAC) & Ripening Status

Low Transverse Cesarean (LTCS) Confined to the lower uterine segment non-contractile tissue. 0.5% to 0.9% (with 1 prior LTCS); ~1.0% to 1.8% (with 2 prior LTCS). Candidate for TOLAC. Mechanical cervical ripening (Foley balloon) permitted. Prostaglandins CONTRAINDICATED.

Low Vertical Cesarean Vertical incision confined strictly to the lower uterine segment. 1.0% to 2.0% TOLAC may be considered after rigorous operative note review confirming incision did not extend into the upper contractile fundus.

Classical (High Vertical) Cesarean Extends vertically through the thick, highly vascular, active contractile myometrium of the fundus. 4.0% to 9.0% (Rupture frequently occurs prior to labor onset). ABSOLUTE CONTRAINDICATION to TOLAC. Scheduled cesarean delivery mandatory at 36 0/7 to 37 0/7 weeks (or earlier if spontaneous contractions occur).

T- or J-Shaped Incisions / Inverted T Extension of low transverse incision vertically into upper contractile segment. 4.0% to 10.0% ABSOLUTE CONTRAINDICATION to TOLAC. Scheduled cesarean delivery at 36 0/7 to 37 0/7 weeks.

Extensive Transmural Myomectomy Myomectomy entering the endometrial cavity, or deep myometrial dissection (>50% wall thickness, extensive electrosurgical coagulation). 3.0% to 8.0% ABSOLUTE CONTRAINDICATION to TOLAC. Scheduled cesarean delivery at 37 0/7 to 38 0/7 weeks. (Superficial subserosal myomectomy is not a contraindication to TOLAC).

Prior Uterine Rupture / Dehiscence Previous complete disruption of the full-thickness uterine wall. 5.0% to 32.0% ABSOLUTE CONTRAINDICATION to TOLAC. Scheduled cesarean delivery at 36 0/7 to 37 0/7 weeks .

  • 6. Substance Use Disorders in Acute Obstetric Emergencies
  • Opioid Use Disorder (OUD) & Pain Management

Medication for Opioid Use Disorder (MOUD): Parturients maintained on Methadone or Buprenorphine must continue their exact baseline maintenance dosage throughout labor, delivery, and postpartum to prevent acute opioid withdrawal (which induces severe uterine hypertonicity, placental abruption, and acute fetal distress).

Acute Pain Management: Baseline MOUD satisfies baseline dependence and does NOT provide analgesia for acute labor pain or surgical delivery. Multimodal analgesia (early continuous neuraxial epidural/spinal, scheduled IV/oral acetaminophen, NSAIDs postpartum) combined with additional full-agonist short-acting opioids (e.g., fentanyl, oxycodone) at higher-than-average doses is required due to opioid receptor down-regulation.

Contraindicated Medications: Mixed opioid agonist-antagonists (e.g., Butorphanol [Stadol] , Nalbuphine [Nubain] ) and opioid antagonists (Naloxone) are strictly contraindicated in opioid-dependent patients as they precipitate acute, violent withdrawal crises.

Acute Stimulant Intoxication (Cocaine & Methamphetamine)

Pathophysiology: Massive adrenergic surge via inhibition of catecholamine reuptake (cocaine) or stimulation of dopamine/norepinephrine release (methamphetamine), causing acute severe hypertension, coronary and uteroplacental vasoconstriction, maternal myocardial ischemia, and abruptio placentae.

Emergency Management:

Administer IV Benzodiazepines (e.g., Lorazepam 1–2 mg or Diazepam 5–10 mg IV) to blunt central sympathetic overdrive, reduce tachycardia, and lower blood pressure.

Control severe hypertension with combined alpha-and-beta blockers ( Labetalol ) or peripheral vasodilators / calcium channel blockers ( Hydralazine, Nifedipine, Nicardipine ).

Strictly AVOID pure beta-adrenergic blockers (e.g., Propranolol, Metoprolol, Esmolol): Unopposed alpha-1 adrenergic stimulation leads to catastrophic, refractory coronary and systemic vasoconstriction, severe hypertensive emergency, and acute aortic dissection.

7. Mental Health Conditions: Screening, Psychiatric Emergencies & the Organic Rule-Out

The NCC outline pairs mental health with substance use under a single assessment bullet for a reason. In the most recent national Maternal Mortality Review Committee (MMRC) data, mental health conditions — comprising suicide, overdose or poisoning related to substance use disorder, and other deaths MMRCs attributed to mental health conditions — were the single leading underlying cause of pregnancy-related death, accounting for roughly 22% to 23% of all pregnancy-related deaths. Among these deaths, essentially every case with a preventability determination was judged preventable, the highest preventability fraction of any cause category. Mental health is therefore not a "soft" screening topic; it is the leading killer on the list.

Validated Screening in the Emergency and Inpatient Setting

ACOG recommends screening for perinatal depression and anxiety with a validated instrument at the initial obstetric visit, later in pregnancy, and at the comprehensive postpartum visit, with any positive screen followed by a diagnostic assessment rather than a screen-and-refer handoff.

Instrument What It Screens Emergency-Relevant Trigger

Edinburgh Postnatal Depression Scale (EPDS) Perinatal depression (10 items) Item 10 asks about self-harm thoughts — any non-zero response mandates an immediate safety assessment before the patient leaves the unit

  • PHQ-9 Depression severity Item 9 (thoughts of being better off dead) is the same red flag
  • GAD-7 Anxiety severity Severe scores predict escalation and poor engagement with follow-up

4 P's / NIDA Quick Screen Substance use Positive screen drives MOUD continuation planning (see Section 6 above)

Postpartum Psychosis: A True Psychiatric Emergency

Onset: Abrupt, typically within the first 2 weeks postpartum , and strongly associated with underlying bipolar disorder.

Presentation: Rapidly fluctuating (delirium-like) course, disorganization, insomnia without fatigue, and delusions or hallucinations that frequently center on the infant. Command or "altruistic" infanticidal delusions carry real risk to both mother and newborn.

Disposition: Immediate psychiatric evaluation and inpatient admission with supervision of any mother-infant contact. This is categorically different from postpartum blues (self-limited, peaks day 3–5, no psychosis) and from postpartum depression (gradual onset, intact reality testing).

The Organic Rule-Out Rule

The most dangerous error in this domain is anchoring on a psychiatric label in a physiologically deteriorating patient. In an obstetric patient with new agitation, confusion, or altered mental status, "psychiatric" is a diagnosis of exclusion. Before attributing behavior to mental illness, exclude:

  • Eclampsia and posterior reversible encephalopathy syndrome
  • Hypoglycemia (point-of-care glucose is mandatory, not optional)
  • Hypoxemia , sepsis, and amniotic fluid embolism
  • Magnesium toxicity , local anesthetic systemic toxicity, opioid or stimulant intoxication
  • Intracranial hemorrhage, ischemic stroke, and cerebral venous sinus thrombosis
  • Ethical and Legal Considerations

Urine toxicology is a medical test requiring consent , not a forensic instrument; punitive or reflexive reporting drives patients away from prenatal care and worsens outcomes. Reporting obligations for substance exposure differ by state, so clinicians must know their own jurisdiction's statute. Document behavior and findings objectively — record what the patient said and did, not a subjective characterization of her character or cooperativeness.

Loading diagram... Maternal Comorbidity Emergency Risk Stratification & Triage Pathway